Piperazinylcamphorsulfonyl oxytocin antagonists

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

514252, 514253, 514254, 514255, 540598, 544 55, 544121, 544230, 544362, 544364, 544365, 544366, 544370, 544371, 544372, 544374, 544383, 544384, 544385, 544391, A61K 31495, C07D29526, C07D40112, C07D40512

Patent

active

056483520

ABSTRACT:
The invention is directed to a series of novel piperazinylcamphorsulfonyl compounds where the camphor ring is substituted by amides, amines, alkanes, alkenes, alkylamines, halogens, hydroxy, carboxy, alkoxycarbonyl and heterocyclic tings. Such compounds are oxytocin antagonists useful in the treatment of preterm labor, dysmenorrhea and for the stoppage of labor preparatory to cesarean delivery.

REFERENCES:
patent: 3301857 (1967-01-01), Berger et al.
patent: 3654287 (1972-04-01), Dykstra et al.
patent: 3666764 (1972-05-01), Campbell et al.
patent: 4087425 (1978-05-01), Garcia et al.
patent: 4147870 (1979-04-01), Garcia et al.
patent: 4379933 (1983-04-01), Ong et al.
patent: 4547505 (1985-10-01), Oepen et al.
patent: 5091387 (1992-02-01), Evans et al.
patent: 5204349 (1993-04-01), Bock et al.
J. of Pharm. Sciences, vol. 71, No. 3 (Mar. 1982), by Crooks, et al., entitled The Synthesis and Analgesic Activities of Some Spiro[Indan-1.3'-Pyrrolidine]Derivatives Designed as Rigid Analogs of Profadol.
J. Org. Chem. vol. 36, 5, pp. 650-654 (1971), by Matier, et al., entitled Novel Cyclizations and Ring-Opening Reactions of 3-Phenylindene Derivatives.
J. Org. Chem. vol. 41, No. 15 (1976), by Parham, et al., entitled Spiro Piperidines, 1 Synthesis of Spiro[Isobenzofuran-1(3H),4'-Piperidines] and Spiro[Isobenzotetrahydrothiophene-1(3H)4'-Piperidines]1.
D. J. Pettibone,et al.,Reg. Peptides (1993), 45, 289-293, entitled Development and Pharmacological Assessment of Novel Peptide and Nonpeptide Oxytocin Antagonists.
B. E. Evans, et al., J. Med. Chem. (1992) 35, 3919-3927, Entitled Orally Active, Nonpeptide Oxytocin Antagonists.
D. J. Pettibone, et al., J. Pharm. Exp. Ther. (1992) 264, 308-314, entitled Identification or an Orally Active, Nonpeptide Oxytocin Antagonist.
D. J. Pettibone, et al., Drug Dev. Res. (1993) 30, 129-142, entitled L-368,899, A Potent Orally Active Oxytocin Antagonist for Potential Use in Preterm Labor.
B. E. Evans, et al., J. Med. Chem. (1993) 36, 3993-4005, entitled Nanomolar-Affinity, Non-Peptide Oxytocin Receptor Antagonists.
M. G. Bock, et al., Vasopressin (1993), J. Libbey Eurotext, pp. 539-547.
J. of Chromatography, 136 (1977) pp. 401-407, by T. Bryce, et al., entitled Gas Liquid Chromatographic Determination of 1.3 Dihydro-3-Phenylspiro[Isobenzofuran-1.4.-Piperidine]HP 505 in Biological Fluids Using a Nitrogen Specific Detector.
Chemical Abstracts, vol. 86, No. 5, p. 376, Abstract No. 29877C, Conde, (1977).
Chemical Abstracts, vol. 78, No. 5, p. 510, Abstract No. 29818U, Laboratorios Liade, (1973).
U.S. application No. 08/093,502 Merck & Co. Inc., filed Jul. 16, 1993.
U.S. application No. 08/153,521 Merck & Co. Inc., filed Nov. 16, 1993.
U.S. application No. 08/030,936 Merck & Co. Inc., filed Mar. 12, 1993.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Piperazinylcamphorsulfonyl oxytocin antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Piperazinylcamphorsulfonyl oxytocin antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperazinylcamphorsulfonyl oxytocin antagonists will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-1492471

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.